Literature DB >> 28069426

Impaired natural killer cell functions in patients with signal transducer and activator of transcription 1 (STAT1) gain-of-function mutations.

Giovanna Tabellini1, Donatella Vairo2, Omar Scomodon3, Nicola Tamassia4, Rosalba Monica Ferraro2, Ornella Patrizi1, Sara Gasperini4, Annarosa Soresina5, Giuliana Giardino6, Claudio Pignata6, Vassilios Lougaris3, Alessandro Plebani3, Laura Dotta3, Marco A Cassatella4, Silvia Parolini1, Raffaele Badolato7.   

Abstract

BACKGROUND: Gain-of-function (GOF) mutations affecting the coiled-coil domain or the DNA-binding domain of signal transducer and activator of transcription 1 (STAT1) cause chronic mucocutaneous candidiasis disease. This condition is characterized by fungal and bacterial infections caused by impaired generation of TH17 cells; meanwhile, some patients with chronic mucocutaneous candidiasis disease might also have viral or intracellular pathogen infections.
OBJECTIVE: We sought to investigate the effect of STAT1 GOF mutations on the functioning of natural killer (NK) cells.
METHODS: Because STAT1 is involved in the signaling response to several cytokines, we studied NK cell functional activities and STAT1 signaling in 8 patients with STAT1 GOF mutations.
RESULTS: Functional analysis of NK cells shows a significant impairment of cytolytic and degranulation activities in patients with STAT1 GOF mutations. Moreover, NK cells from these patients display lower production of IFN-γ in response to IL-15 and reduced proliferation after stimulation with IL-2 or IL-15, suggesting that STAT5 signaling is affected. In addition, signaling studies demonstrate that the increased phosphorylation of STAT1 in response to IFN-α is associated with detectable activation of STAT1 and increased STAT1 binding to the interferon-induced protein with tetratricopeptide repeats 1 (IFIT1) promoter in response to IL-15, whereas STAT5 phosphorylation and DNA binding to IL-2 receptor α (IL2RA) are reduced or not affected in response to the same cytokine.
CONCLUSION: These observations suggest that persistent activation of STAT1 might affect NK cell proliferation and functional activities.
Copyright © 2017 American Academy of Allergy, Asthma & Immunology. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  IL-15; Natural killer cells; candidiasis; cytotoxic activity; signal transducer and activator of transcription 1; signal transducer and activator of transcription 5

Mesh:

Substances:

Year:  2017        PMID: 28069426     DOI: 10.1016/j.jaci.2016.10.051

Source DB:  PubMed          Journal:  J Allergy Clin Immunol        ISSN: 0091-6749            Impact factor:   10.793


  23 in total

1.  Increased STAT1 Amounts Correlate with the Phospho-STAT1 Level in STAT1 Gain-of-function Defects.

Authors:  Andrea R Bernasconi; Judith Yancoski; Mariana Villa; Matías M Oleastro; Miguel Galicchio; Jorge G Rossi
Journal:  J Clin Immunol       Date:  2018-10-09       Impact factor: 8.317

Review 2.  Human inborn errors of immunity to herpes viruses.

Authors:  Emmanuelle Jouanguy; Vivien Béziat; Trine H Mogensen; Jean-Laurent Casanova; Stuart G Tangye; Shen-Ying Zhang
Journal:  Curr Opin Immunol       Date:  2020-01-31       Impact factor: 7.486

3.  Patients With Natural Killer (NK) Cell Chronic Active Epstein-Barr Virus Have Immature NK Cells and Hyperactivation of PI3K/Akt/mTOR and STAT1 Pathways.

Authors:  Matthew K Howe; Kennichi Dowdell; Hye Sun Kuehn; Qingxue Li; Geoffrey T Hart; Doreen Garabedian; Kelly Liepshutz; Amy P Hsu; Hua Su; Julie E Niemela; Jennifer L Stoddard; Gulbu Uzel; Evan Shereck; Laura Schulz; Tatyana Feldman; Sergio D Rosenzweig; Eric O Long; Lesia Dropulic; Jeffrey I Cohen
Journal:  J Infect Dis       Date:  2020-09-01       Impact factor: 5.226

Review 4.  Advances and highlights in primary immunodeficiencies in 2017.

Authors:  Javier Chinen; Morton J Cowan
Journal:  J Allergy Clin Immunol       Date:  2018-08-29       Impact factor: 10.793

5.  Ruxolitinib partially reverses functional natural killer cell deficiency in patients with signal transducer and activator of transcription 1 (STAT1) gain-of-function mutations.

Authors:  Alexander Vargas-Hernández; Emily M Mace; Ofer Zimmerman; Christa S Zerbe; Alexandra F Freeman; Sergio Rosenzweig; Jennifer W Leiding; Troy Torgerson; Matthew C Altman; Edith Schussler; Charlotte Cunningham-Rundles; Ivan K Chinn; Alexandre F Carisey; Imelda C Hanson; Nicholas L Rider; Steven M Holland; Jordan S Orange; Lisa R Forbes
Journal:  J Allergy Clin Immunol       Date:  2017-10-27       Impact factor: 10.793

Review 6.  Human STAT1 Gain-of-Function Heterozygous Mutations: Chronic Mucocutaneous Candidiasis and Type I Interferonopathy.

Authors:  Satoshi Okada; Takaki Asano; Kunihiko Moriya; Stephanie Boisson-Dupuis; Masao Kobayashi; Jean-Laurent Casanova; Anne Puel
Journal:  J Clin Immunol       Date:  2020-08-27       Impact factor: 8.317

Review 7.  JAK/STAT signaling in regulation of innate lymphoid cells: The gods before the guardians.

Authors:  Helena Stabile; Gianluca Scarno; Cinzia Fionda; Angela Gismondi; Angela Santoni; Massimo Gadina; Giuseppe Sciumè
Journal:  Immunol Rev       Date:  2018-11       Impact factor: 12.988

8.  Utility of Ruxolitinib in a Child with Chronic Mucocutaneous Candidiasis Caused by a Novel STAT1 Gain-of-Function Mutation.

Authors:  Markéta Bloomfield; Veronika Kanderová; Zuzana Paračková; Petra Vrabcová; Michael Svatoň; Eva Froňková; Martina Fejtková; Radana Zachová; Michal Rataj; Irena Zentsová; Tomáš Milota; Adam Klocperk; Tomáš Kalina; Anna Šedivá
Journal:  J Clin Immunol       Date:  2018-06-22       Impact factor: 8.317

Review 9.  The Impact of Immunodeficiency on NK Cell Maturation and Function.

Authors:  Alexander Vargas-Hernández; Lisa R Forbes
Journal:  Curr Allergy Asthma Rep       Date:  2019-01-19       Impact factor: 4.806

10.  Risks of Ruxolitinib in STAT1 Gain-of-Function-Associated Severe Fungal Disease.

Authors:  Ofer Zimmerman; Berenice Rösler; Christa S Zerbe; Lindsey B Rosen; Amy P Hsu; Gulbu Uzel; Alexandra F Freeman; Elizabeth P Sampaio; Sergio D Rosenzweig; Hye Sun Kuehn; Tiffany Kim; Kristina M Brooks; Parag Kumar; Xiaowen Wang; Mihai G Netea; Frank L van de Veerdonk; Steven M Holland
Journal:  Open Forum Infect Dis       Date:  2017-09-22       Impact factor: 3.835

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.